Intrasense, a French expert in AI-enhanced medical imaging solutions that facilitate and secure diagnosis, decision-making, and therapeutic follow-up, announces its consolidated sales for the first half of fiscal year 2025.

Intrasense (ISIN : FR0011179886 – Mnémo : ALINS), a French expert in AI-enhanced medical imaging solutions that facilitate and secure diagnostics, decision-making, and therapeutic follow-up, provides an update on its activities two months after announcing its strategic roadmap

Intrasense (ISIN : FR0011179886 – Mnémo : ALINS), the French expert in AI-enhanced medical imaging solutions that facilitate and secure diagnosis, decision-making and therapeutic follow-up (the “Company”), announces a change in the composition of its Board of Directors

Intrasense (ISIN : FR0011179886 – Mnémo : ALINS), the French expert in AI-enhanced medical imaging solutions that facilitate and secure diagnosis, decision-making and therapeutic follow-up, announces that it has obtained CE marking under MDR (Medical Device Regulation) for Myrian^® 2.14, the new version of its advanced radiology visualization solution. This new CE marking for Intrasense's innovative solutions is fully in line with the Group's strategic roadmap, based on four pillars: innovation, product range extension, geographical expansion and financial control.

Intrasense (ISIN : FR0011179886), a French expert in medical imaging solutions facilitating diagnosis, decision-making, and therapeutic follow-up, announces the publication of its 2024 annual results and its new strategic roadmap. These financial statements were approved on March 25, 2025, by the Board of Directors. The audit procedures on the consolidated accounts have been completed, and the certification report was issued on March 26 by the statutory auditors.